Clinical Trial Update: Lentivirally Redirected CD123 Autologous T Cells in AML [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating lentivirally redirected CD123 autologous T cells for acute myeloid leukemia; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Lentivirally Redirected CD123 Autologous T Cells

Snippet

Sponsor: University of Pennsylvania | Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Adult | Phase 1 | Status: ACTIVE_NOT_RECRUITING